AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for new ways forward

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)

Pfizer is targeting a steady 2025, promising pipeline trims, cost cuts and smaller deals as it works to reassure investors about its path forward. …

December 18, 2024

Ascend Grows Q2 Revenue 15%

AWH ANNOUNCES Q2 2024 FINANCIAL RESULTS Achieved $141.5M Net Revenue in Q2 2024, a 15% Increase Year-Over-Year Reported $28.3 million in Adjusted EBITDA, a 33%

August 5, 2024

MarketingRx roundup: Pfizer, Astellas’ Super Bowl spots; Lilly debuts new Alzheimer’s ad

Pfizer hits the mark with Queen and science: Pfizer announced a last-minute jump into the Super Bowl lineup the day before it aired a celebratory

February 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.